

Market Outlook

The Nifty 50 closed at 25,597, extending its profit-booking phase and ending the session on a negative note. On the daily chart, the index slipped below the crucial 25,600 level, which aligns with the 20-day EMA, signalling a bearish momentum in the near term. Derivatives data for the upcoming weekly expiry indicates fresh Call OI build-up at the 25,700 and 25,800 strikes, highlighting immediate resistance zones. On the downside, notable Put OI Buildup at the 25,200 and 25,000 levels suggests key support area.

Key Indices Update

INDEX	CLOSE	CHANGE (%)
NIFTY	25597.65	-0.64
SENSEX	83459.15	-0.62
BANKNIFTY	57827.05	-0.47
INDIA VIX	12.65	-0.10

FII's STATISTICS


FII's F&O Data

Sector	Buy/Sell	Change in OI
Index Futures	-2023.25	7.13%
Index Options	58579.73	-36.96%
Stock Futures	-4671.63	0.37%
Stock Options	857.13	8.74%

FII's & DII's Cash Segment (Rs. In Crore)

Category	Amount	MTD	YTD
FII	-1067.01	-2951	-113171
DII	1202.90	4719	447169

FII's Activity in Index Future



Amt in Crores


NIFTY 50 HIGH DELIVERY STOCKS

SYMBOL	DELIVERABLE QTY	CHG IN DLY RATIO VS PREV DAY	% CHG IN TRD QTY OVER PREV DAY
ETERNAL	24956097	12.61	5.52
POWERGRID	17869185	3.39	204.24
HDFCBANK	10792510	-6.29	20.58
TATASTEEL	10481402	11.43	12.58
ICICIBANK	9647498	0.32	37.39
BEL	7992405	13	-52.86
NTPC	7898395	3.03	16.06
BHARTIARTL	7568409	4.43	311.56
ITC	6914720	10.78	32.09
COALINDIA	6791149	-10.44	-25.55


NIFTY

Nifty	25708.30
OI (In contracts)	254386
CHANGE IN OI (%)	5.70
PRICE CHANGE (%)	-0.70
IMPLICATION	SHORT BUILDUP

NIFTY (CLOSE VS OI)



NIFTY OPTION CHAIN




Long Buildup

Symbol	Price	Price %	OI	OI %
POWERINDIA	20473	14.10	4036	32.50
DIVISLAB	6840	0.00	30244	10.40
SBIN	962.2	0.90	114277	5.60
DELHIVERY	486.25	2.40	9594	5.20
M&M	3597.8	0.80	104328	3.00


BANKNIFTY

Banknifty	58117.80
OI (In contracts)	55055
CHANGE IN OI (%)	-0.90
PRICE CHANGE (%)	-0.50
IMPLICATION	LONG UNWINDING

BANKNIFTY (CLOSE VS OI)



BANKNIFTY OPTION CHAIN



Short Buildup

Symbol	Price	Price %	OI	OI %
HEROMOTOCO	5336	-4.20	33622	16.20
PIIND	3696.1	-0.30	11401	11.30
DIVISLAB	6840	0.00	30244	10.40
TMPV	406.35	-2.80	61374	9.00
PPLPHARMA	200.03	-0.50	9001	6.70

Top 10 High PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
PETRONET	14448600	10708200	1.35
BHEL	42120750	34062000	1.24
POWERINDIA	304800	260050	1.17
CANBK	105225750	94324500	1.12
IOC	58656000	53049750	1.11
ALKEM	169500	157625	1.08
HINDALCO	13792800	13047300	1.06
JINDALSTEL	5197500	4935000	1.05
SHRIRAMFIN	14355825	13664475	1.05
AUBANK	4651000	4457000	1.04

Top 10 Low PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
GMRAIRPORT	36821025	123813225	0.3
MARUTI	1358600	3927400	0.35
PATANJALI	4738500	12676500	0.37
MAZDOCK	1615450	4287675	0.38
NESTLEIND	1781500	4653500	0.38
KFINTECH	1671650	4319550	0.39
SHREECEM	43675	113200	0.39
YESBANK	157645900	401252200	0.39
PPLPHARMA	5017500	12097500	0.41
BHARTIARTL	6827175	16158075	0.42

NIFTY 50 SUPPORT-RESISTANCE LEVELS

SYMBOL	R1	R2	PP	S1	S2
ADANIENT	2486	2547	2441	2381	2335
ADANIPORTS	1467	1485	1451	1433	1417
APOLLOHOSP	7890	7948	7846	7787	7743
ASIANPAINT	2521	2547	2503	2477	2459
AXISBANK	1240	1249	1234	1225	1219
BAJAJ-AUTO	8891	9010	8819	8700	8628
BAJAJFINSV	2102	2125	2087	2065	2050
BAJFINANCE	1071	1083	1054	1042	1025
BEL	422	427	419	414	411
BHARTIARTL	2140	2162	2120	2098	2078
CIPLA	1525	1539	1514	1500	1490
COALINDIA	381	384	379	377	375
DRREDDY	1203	1207	1199	1195	1191
EICHERMOT	7039	7136	6983	6886	6831
ETERNAL	321	327	318	312	308
GRASIM	2912	2932	2898	2878	2864
HCLTECH	1544	1555	1537	1525	1518
HDFCBANK	997	1004	993	986	982
HDFCLIFE	752	759	745	739	732
HINDALCO	848	860	841	828	821
HINDUNILVR	2452	2467	2442	2428	2418
ICICIBANK	1353	1364	1347	1337	1330
INDIGO	5711	5785	5652	5578	5519
INFY	1469	1481	1462	1451	1444
ITC	415	419	413	409	406

SYMBOL	R1	R2	PP	S1	S2
JIOFIN	307	311	304	300	298
JSWSTEEL	1199	1212	1189	1175	1166
KOTAKBANK	2122	2137	2113	2098	2088
LT	3986	4028	3962	3919	3896
M&M	3647	3696	3601	3552	3506
MARUTI	15622	15791	15528	15359	15265
MAXHEALTH	1158	1172	1148	1134	1125
NESTLEIND	1277	1285	1267	1259	1249
NTPC	333	337	330	327	324
ONGC	257	260	255	251	249
POWERGRID	280	285	278	273	270
RELIANCE	1493	1506	1485	1473	1465
SBILIFE	1991	2008	1980	1964	1953
SBIN	969	975	957	951	939
SHRIRAMFIN	807	820	799	786	778
SUNPHARMA	1716	1733	1701	1684	1668
TATACONSUM	1208	1234	1176	1150	1117
TATASTEEL	183	185	181	179	177
TCS	3030	3061	3010	2978	2959
TECHM	1426	1439	1418	1405	1398
TITAN	3870	3917	3800	3753	3683
TMPV	415	424	410	401	396
TRENT	4726	4778	4692	4640	4606
ULTRACEMCO	11952	12050	11892	11794	11734
WIPRO	241	243	239	237	236

Research Team

Name	Email ID
<i>Ajit Mishra</i>	ajit.mishra@religare.com
<i>Abhijeet Banerjee</i>	abhijeet.banerjee@religare.com
<i>Gaurav Sharma</i>	gauravsharma2@religare.com
<i>Ashwani Harit</i>	ashwani.harit@religare.com
<i>Divya Parmar</i>	divya.parmar@religare.com
<i>Rajan Gupta</i>	rajan.gupta1@religare.com
<i>Vivek Chandra</i>	vivek.chandra@religare.com
<i>Himanshu Gupta</i>	himanshu.gupta1@religare.com
<i>Vishvajeet Singh</i>	vishvajeet.singh1@religare.com

Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <https://www.religareonline.com/disclaimer>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest if answer to F(a) above is Yes:

..... Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results